These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 15692103)
41. Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface. Bizik J; Trancikova D; Felnerova D; Verheijen JH; Vaheri A Biochem Biophys Res Commun; 1997 Oct; 239(1):322-8. PubMed ID: 9345318 [TBL] [Abstract][Full Text] [Related]
42. Soluble expression of active recombinant human tissue plasminogen activator derivative (K2S) in Escherichia coli. Luo XG; Tian WJ; Ni M; Jing XL; Lv LH; Wang N; Jiang Y; Zhang TC Pharm Biol; 2011 Jun; 49(6):653-7. PubMed ID: 21554008 [TBL] [Abstract][Full Text] [Related]
43. Expression of recombinant kringle 1-5 domains of human plasminogen by a prokaryote expression system. Hou WH; Fang T; Chai YR; Wang TY; Wang JM; Xue LX Protein Expr Purif; 2006 May; 47(1):93-8. PubMed ID: 16510293 [TBL] [Abstract][Full Text] [Related]
44. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. MacDonald NJ; Murad AC; Fogler WE; Lu Y; Sim BK Biochem Biophys Res Commun; 1999 Oct; 264(2):469-77. PubMed ID: 10529387 [TBL] [Abstract][Full Text] [Related]
45. p22 is a novel plasminogen fragment with antiangiogenic activity. Kwon M; Yoon CS; Fitzpatrick S; Kassam G; Graham KS; Young MK; Waisman DM Biochemistry; 2001 Nov; 40(44):13246-53. PubMed ID: 11683633 [TBL] [Abstract][Full Text] [Related]
46. Cloning and expression of truncated form of tissue plasminogen activator in Leishmania tarentolae. Nazari R; Davoudi N Biotechnol Lett; 2011 Mar; 33(3):503-8. PubMed ID: 21120587 [TBL] [Abstract][Full Text] [Related]
47. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784 [TBL] [Abstract][Full Text] [Related]
48. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903 [TBL] [Abstract][Full Text] [Related]
49. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Sim BK; O'Reilly MS; Liang H; Fortier AH; He W; Madsen JW; Lapcevich R; Nacy CA Cancer Res; 1997 Apr; 57(7):1329-34. PubMed ID: 9102221 [TBL] [Abstract][Full Text] [Related]
50. Kringle 5 peptide-albumin conjugates with anti-migratory activity. Léger R; Benquet C; Huang X; Quraishi O; van Wyk P; Bridon D Bioorg Med Chem Lett; 2004 Feb; 14(4):841-5. PubMed ID: 15012978 [TBL] [Abstract][Full Text] [Related]
51. Mechanism of angiogenic effects of saponin from ginseng Radix rubra in human umbilical vein endothelial cells. Morisaki N; Watanabe S; Tezuka M; Zenibayashi M; Shiina R; Koyama N; Kanzaki T; Saito Y Br J Pharmacol; 1995 Aug; 115(7):1188-93. PubMed ID: 7582543 [TBL] [Abstract][Full Text] [Related]
52. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725 [TBL] [Abstract][Full Text] [Related]
53. Modes of evolution in the protease and kringle domains of the plasminogen-prothrombin family. Hughes AL Mol Phylogenet Evol; 2000 Mar; 14(3):469-78. PubMed ID: 10712851 [TBL] [Abstract][Full Text] [Related]
54. The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Shim BS; Kang BH; Hong YK; Kim HK; Lee IH; Lee SY; Lee YJ; Lee SK; Joe YA Biochem Biophys Res Commun; 2005 Feb; 327(4):1155-62. PubMed ID: 15652516 [TBL] [Abstract][Full Text] [Related]
55. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain. O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916 [TBL] [Abstract][Full Text] [Related]
56. Complexation of the tissue plasminogen activator protease with benzamidine-type inhibitors: interference by the kringle 2 module. Hu CK; Kohnert U; Sturzebecher J; Fischer S; Llinas M Biochemistry; 1996 Mar; 35(10):3270-6. PubMed ID: 8605163 [TBL] [Abstract][Full Text] [Related]
57. Structure and function of human tissue-type plasminogen activator (t-PA). van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031 [TBL] [Abstract][Full Text] [Related]
58. Human plasminogen kringle 1-5 inhibits angiogenesis and induces thrombomodulin degradation in a protein kinase A-dependent manner. Cho CF; Chen PK; Chang PC; Wu HL; Shi GY J Mol Cell Cardiol; 2013 Oct; 63():79-88. PubMed ID: 23880609 [TBL] [Abstract][Full Text] [Related]
59. The recombinant kringle domain of urokinase plasminogen activator inhibits VEGF165-induced angiogenesis of HUVECs by suppressing VEGFR2 dimerization and subsequent signal transduction. Kim BM; Lee DH; Choi HJ; Lee KH; Kang SJ; Joe YA; Hong YK; Hong SH IUBMB Life; 2012 Mar; 64(3):259-65. PubMed ID: 22252975 [TBL] [Abstract][Full Text] [Related]
60. Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain. Gething MJ; Adler B; Boose JA; Gerard RD; Madison EL; McGookey D; Meidell RS; Roman LM; Sambrook J EMBO J; 1988 Sep; 7(9):2731-40. PubMed ID: 2846282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]